MX2016007066A - Identification of predictive biomarkers associated with wnt pathway inhibitors. - Google Patents

Identification of predictive biomarkers associated with wnt pathway inhibitors.

Info

Publication number
MX2016007066A
MX2016007066A MX2016007066A MX2016007066A MX2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A
Authority
MX
Mexico
Prior art keywords
wnt pathway
identification
pathway inhibitors
biomarkers associated
predictive biomarkers
Prior art date
Application number
MX2016007066A
Other languages
Spanish (es)
Inventor
M Kapoun Ann
Zhang Chun
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2016007066A publication Critical patent/MX2016007066A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides biomarkers for identifying tumors likely to respond to treatment with Wnt pathway inhibitors. Also provided are methods for identifying tumors and/or patients that are likely to be responsive or non-responsive to treatment with a Wnt pathway inhibitor. Methods for treating a patient with cancer are provided, wherein the cancer is predicted to respond to a Wnt pathway inhibitor.
MX2016007066A 2013-12-02 2014-12-02 Identification of predictive biomarkers associated with wnt pathway inhibitors. MX2016007066A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910663P 2013-12-02 2013-12-02
US201461975339P 2014-04-04 2014-04-04
PCT/US2014/068097 WO2015084808A1 (en) 2013-12-02 2014-12-02 Identification of predictive biomarkers associated with wnt pathway inhibitors

Publications (1)

Publication Number Publication Date
MX2016007066A true MX2016007066A (en) 2016-09-08

Family

ID=53274023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007066A MX2016007066A (en) 2013-12-02 2014-12-02 Identification of predictive biomarkers associated with wnt pathway inhibitors.

Country Status (9)

Country Link
EP (1) EP3077546A4 (en)
JP (1) JP2017501137A (en)
CN (1) CN105829547A (en)
AU (1) AU2014357354A1 (en)
CA (1) CA2931975A1 (en)
HK (1) HK1223657A1 (en)
MX (1) MX2016007066A (en)
TW (1) TW201610168A (en)
WO (1) WO2015084808A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US20180223372A1 (en) * 2015-08-03 2018-08-09 Oncomed Pharmaceutical, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
SG10202002323UA (en) * 2015-09-16 2020-05-28 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
RU2019115946A (en) * 2016-10-26 2020-11-27 Лип Терапьютикс, Инк. THE APPLICATION OF BETA-CATENIN AS A BIOMARKER FOR THE TREATMENT OF CANCER WITH THE ANTIBODY TO DKK-1
CN106990245B (en) * 2017-04-05 2018-07-31 东南大学 Detect application of the reagent of PITX1 expression quantity in preparing gastric cancer prognosis evaluation reagent kit
CN110835372B (en) * 2019-11-06 2020-12-01 上海健康医学院 Targeting Frizzled7 monoclonal antibody, and preparation method and application thereof
CN111735949B (en) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a and CA125 combined as early ovarian cancer biomarker and kit
CN115337400A (en) * 2021-05-13 2022-11-15 中国科学院分子细胞科学卓越创新中心 Reagent for diagnosing and treating tumor and its use
CN113293212A (en) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 Primer probe for detecting amplification of neuroblastoma recurrence transfer gene FZD2 and application thereof
WO2023113013A1 (en) * 2021-12-17 2023-06-22 国立大学法人京都大学 Method for selecting gene for use in estimation of possibility of onset of disease, and method for estimating possibility of onset of disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO2001002568A2 (en) * 1999-07-02 2001-01-11 Chiron Corporation Human genes and gene expression products
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7723112B2 (en) 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
BRPI0714751A2 (en) 2006-09-08 2014-06-24 Genentech Inc "WNT ANTAGONISTS, COMPOSITION, NUCLEIC ACID, VECTOR, HOST CELL, MANUFACTURED ARTICLE, WNT SIGNALING INHIBIT METHOD, METHOD FOR DETECTING THE PRESENCE OF UAM PROTEIN TO A WAY TO EXT MÉTLE A MÉTO MÉTONE THERAPEUALLY TREATING A WNT-MEDIATED CANCER AND USES OF WNT ANTAGONISTS IN MANUFACTURING A MEDICINAL PRODUCT "
ME02371B (en) 2006-09-29 2016-06-20 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
EP2084296B1 (en) * 2006-09-29 2015-08-05 Agendia N.V. High-throughput diagnostic testing using arrays
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
AU2009296246B2 (en) * 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20100169025A1 (en) * 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway
WO2010101793A2 (en) * 2009-03-06 2010-09-10 University Of South Alabama Methods and compositions for the diagnosis, prognosis and treatment of cancer
EP2523974A4 (en) 2010-01-12 2013-11-06 Oncomed Pharm Inc Wnt-binding agents and uses thereof
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
US20150132301A1 (en) * 2011-12-09 2015-05-14 Oncomed Pharmaceuticals, Inc. Combination Therapy for Treatment of Cancer

Also Published As

Publication number Publication date
HK1223657A1 (en) 2017-08-04
EP3077546A1 (en) 2016-10-12
EP3077546A4 (en) 2017-04-26
AU2014357354A1 (en) 2016-06-09
CA2931975A1 (en) 2015-06-11
TW201610168A (en) 2016-03-16
WO2015084808A1 (en) 2015-06-11
JP2017501137A (en) 2017-01-12
WO2015084808A4 (en) 2015-08-13
CN105829547A (en) 2016-08-03

Similar Documents

Publication Publication Date Title
MX2016007066A (en) Identification of predictive biomarkers associated with wnt pathway inhibitors.
IL261353A (en) Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
PH12017500293A1 (en) Boronic acid derivatives
HK1213189A1 (en) Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
MX2017004043A (en) Boronic acid derivatives.
MX2017004037A (en) Boronic acid derivatives.
SG11201607448PA (en) Determining cancer agressiveness, prognosis and responsiveness to treatment
MX370336B (en) Boronic acid derivatives.
EP3394032A4 (en) Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
MX2018006781A (en) Mat2a inhibitors for treating mtap null cancer.
EA201690007A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
MX2015014660A (en) Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors.
EA201491699A1 (en) CANCER TREATMENT WITH TOR KINASE INHIBITORS
EA201491701A1 (en) CANCER TREATMENT WITH TOR KINASE INHIBITORS
EA201591278A1 (en) COMPOSITIONS CONTAINING C1-INH, AND METHODS OF PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH THE DEFICIENCY C1 inhibitor
MX2014011500A (en) Diagnosis and treatments relating to her3 inhibitors.
MX2015011428A (en) Methods of treating and preventing cancer drug resistance.
TN2019000212A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
MX365512B (en) Predictive biomarker for cancer therapy.
BR112016025040A2 (en) methods to determine mit biomarker expression, to treat cancer, to identify an individual with cancer, to predict whether an individual with cancer is more or less likely to respond effectively to treatment, to inhibit cell proliferation, and to treat nccrcc in an individual
MA40636A (en) Methods of detecting prostate cancer
JO3730B1 (en) Use of pan FGFR inhibitors and method of identifying patients with cancer eligible for treatment with a pan FGFR inhibitor
MX2016009655A (en) Novel methods for treating cancer.